BHITS is a Delaware Corporation formed on August 16, 2017 for the general purpose of providing regenerative medical services and performing research and development of related products and services. This is a new entity, with limited assets and significant liabilities, whose ongoing operations will be funded primarily by the proceeds of this and future offerings, after having been funded to date by its founders and initial investors.

BHITS was formed to perform research regarding, and to monetize, stem cell technology and associated regenerative medicine. Stem cells are an area of active scientific research. Researchers are studying their potential future applications in medicine; these potential applications are investigational, and their safety and effectiveness have not been established.

Stem cell and regenerative-medicine research is an active field of scientific study. BHITS is led by an experienced science and medical team and collaborates with international research partners. Our activities are focused on investigational research; the safety and effectiveness of these approaches have not been established, and they are not intended to diagnose, treat, cure, or prevent any disease.

A study involving human umbilical cord blood cells has been registered on ClinicalTrials.gov (Identifier: NCT03735277). There is no IND in effect, and registration on ClinicalTrials.gov does not indicate FDA approval or endorsement.

BHIAG is a Swiss holding company formed on December 29, 2010. In prior research activity, human umbilical cord blood-derived and adipose-derived cells were studied in research subjects. These were investigational research activities conducted under ethical oversight; no safety or efficacy conclusions should be drawn, and outcomes have not been established.

Dr. Brian Mehling is the founder of BHITS and BHIAG and is a globally recognized presence in the regenerative medicine research community. Dr. Mehling has previously founded BHI companies in Germany, Slovakia, Belize, Brazil, Jamaica, Seychelles and Israel; with Monaco, Germany and Israel up next. With BHITS, Dr. Mehling and his team are bringing their global experience to the United States. BHITS is the only Blue Horizon company licensed in the U.S. to utilize the broad swath of intellectual property created by BHIAG, as all intellectual property generated by BHIAG’s overseas entities is exclusively licensed to BHITS for domestic operations.

BHITS will be conducting all United States business related to the Blue Horizon family of businesses, research and monetization of stem cell technology and associated regenerative medicine. BHITS will also be the sole conduit for the U.S. for all internationally developed Blue Horizon intellectual property. BHITS is also the sole U.S. distributor of the Alpha Blu cosmetic line, a line of products developed in Germany because of Blue Horizon’s stem cell research.

BHITS and BHIAG do not use fetal or embryonic stem cells, but rather use only adult (somatic) stem cells and human umbilical cord blood stem cells that are ethically harvested from umbilical cord collected after birth with no harm to mother or baby. BHIAG has become one of the pioneers of the use of stem cells obtained from human umbilical cord blood, human umbilical cord tissue, and from a patients’ own fat or bone marrow.

Please email invest@bhiscienes.com for more information.

Any decision to invest should be based solely on the official offering materials and the risk factors described therein. Nothing on this website is an offer to sell or a solicitation of an offer to buy any security. Our products are investigational and are not FDA-approved.

Download our Investment Package:

BHIAG and BHITS Investment Package

and check out our Crowdfunder and Angel List pages